Targeted attack on cancer cells during transplant shows promise
NCT ID NCT03856216
Summary
This study tested whether adding a targeted drug called inotuzumab ozogamicin to a stem cell transplant regimen could better control leukemia and lymphoma. The drug is designed to seek out and kill cancer cells that have a specific marker (CD22). Researchers enrolled 15 patients with certain blood cancers to assess the safety of giving this drug both before and after the transplant. The study was terminated early, and participants needed to take anti-rejection medications for about six months after the procedure.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.